Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 20, Issue SUPPL. 4, 2009, Pages

  Stupp, R ^a   Roila, F ^b  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b S MARIA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBAMAZEPINE; DEXAMETHASONE; ERLOTINIB; LOMUSTINE; METHYLGUANINE METHYLTRANSFERASE; METHYLTRANSFERASE; NITROSOUREA; PHENOBARBITAL; PHENYTOIN; PROCARBAZINE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VINCRISTINE;

ADJUVANT THERAPY; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; EPIGENETICS; FOLLOW UP; GENE SILENCING; GLIOBLASTOMA; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUMBAR PUNCTURE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROMOTER REGION; RISK ASSESSMENT; SEIZURE; STEROID THERAPY; TUMOR BIOPSY;

BRAIN NEOPLASMS; EUROPE; FOLLOW-UP STUDIES; GLIOMA; HEALTH PLANNING GUIDELINES; HUMANS; SOCIETIES, MEDICAL; TREATMENT OUTCOME;

EID: 66549083540     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp151     Document Type: Article

References (28)

1. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008; 359: 492-507.
2. Louis D, Ohgaki H, Wiestler O, Cavenee WK. WHO Classification of Tumours of the Central Nervous System. Lyon: IARC 2007.
3. Stupp R, Hegi ME, Gilbert MR, Chakravarti A. Chemoradiotherapy in malignant glioma: Standard of care and future directions. J Clin Oncol 2007; 25: 4127-4136.
4. Stupp R, Hottiner AF, vand den Bent MJ et al. Frequently asked questions in the medical management of high-grade glioma: A short guide with practical answers ESMO Educational Book 2008. Ann Oncol 2008; 19 (Suppl 7): Vii209-vii216.
5. Stummer W, Pichlmeier U, Meinel T et al. Fluorescence-guided surgery with 5aminolevulinic acid for resection of malignant glioma: A randomised controlled multicentre phase III trial. Lancet Oncol 2006; 7: 392-401.
6. Lacroix M, Abi-Said D, Fourney DR et al. A multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis, extent of resection, and survival. J Neurosurg 2001; 95: 190-198.
7. Westphal M, Hilt DC, Bortey E et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-Oncol 2003; 5: 79-88.
8. Westphal M, Ram Z, Riddle V et al. Gliadel wafer in initial surgery for malignant glioma: Long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien) 2006; 148: 269-275.
9. Stewart LA. Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002; 359: 1011-1018.
10. Medical Research Council Brain Tumor Working Party. Randomized trial of procarbazine, lomustine and vincristine in the adjuvant treatment of high-grade astrocytomaa Medical Research Council trial. J Clin Oncol 2001; 19: 509-518.
11. Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: A prospective randomized clinical trial. J Clin Oncol 2004; 22: 1583-1588.
12. Stupp R, Mason WP. van den Bent MJ et al. Concomitant and adjuvant temozolomide and radiotherapy for newly diagnosed glioblastoma multiforme. N Engl J Med 2005; 352: 987-996.
13. Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003.
14. Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med 2007; 356: 1527-1535.
15. Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008; 26: 2192-2197.
16. Brandsma D, Stalpers L, Taal W et al. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008; 9: 453-461.
17. van den Bent MJ, Carpentier AF, Brandes AA et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A randomized European Organization for Research and Treatment of Cancer phase III trial. J Clin Oncol 2006; 24: 2715-2722.
18. Cairncross G, Berkey B, Shaw E et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 2006; 24: 2707-2714.
19. Wick W, Weller M. for the Neurooncology Working Group of the German Cancer Society. Randomized phase III study of sequential radiochemotherapy of oligoastrocytic tumors of WHO-grade III with PCV or temozolomide: NOA-04. Proc Am Soc Clin Oncol J Clin Oncol. 26. 2008 LBA 2007.
20. Jaeckle KA, Ballman KV, Rao RD et al. Current strategies in treatment of oligodendroglioma: Evolution of molecular signatures of response. J Clin Oncol 2006; 24: 1246-1252.
21. van den Bent MJ, Taphoorn MJ, Brandes AA et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 2003; 21: 2525-2528.
22. Yung WK, Albright RE, Olson J et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000; 83: 588-593.
23. Brandes AA, Tosoni A, Basso U et al. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: A phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol 2004; 22: 4727-4734.
24. Cloughesy T, Prados M, Wen P et al. A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). Proc Am Soc Clin Oncol J Clin Oncol 2008: 26 abstr 2010b.
25. Dresemann G, Mark Rosenthal M, Klaus Höffken K et al. Imatinib plus hydroyurea versus hydroxyurea monotherapy in progressive glioblastoma - an international open label randomised phase III study (AMBROSIA-study). Neuro-Oncology 2007; 9: 519 abstr MA-17.
26. van den Bent M, Brandes A, Rampling R et al. Randomized phase II trial of erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme: EORTC 26034. ASCO Ann Meet Proc Part I. J Clin Oncol. 25. 2007; 76S-Abstr 2004.
27. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8: 1277-1280.
28. Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999; 17: 2572.